ADGRF3

Across TCGA pan-cancer cohorts, ADGRF3 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ADGRF3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ADGRF3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRF3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ESCA, ACC, and UCEC are the cancer types where ADGRF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.158	0.707	<.001	48	view →
ACC	DFS	Median	II,III,IV	0.048	0.632	<.001	15	view →
UCEC	DFS	Median	All	0.843	0.627	.007	14	view →
CESC	OS	Median	II,III,IV	0.227	0.759	.029	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	All	0.251	0.647	.013	6	view →
SKCM	DFS	Median	II,III,IV	0.823	0.539	.023	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.407	.030	5	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ADGRF3–ESCA (OS)

Open the ESCA breakdown →